Reed Jobs, son of Steve Jobs, is steering clear of his famous last name to focus on his passion: curing cancer through biotechnology. Since launching Yosemite in 2023, an oncology-focused venture firm, he has grown the team to 17 members and pursued an innovative strategy combining philanthropy and investment to incubate biotech startups emerging from academic research. Yosemite's portfolio includes promising companies like Azalea, stemming from Jennifer Doudna’s lab, and Quarry, which explores a novel therapeutic approach called induced proximity to disable disease-causing proteins. Jobs is particularly excited about the integration of AI, which has accelerated drug discovery and transformed clinical trial design, reshaping the biotech landscape faster than he anticipated.

Yosemite recently closed the first round of its second fund, aiming to raise $350 million, with about one-third earmarked for building new companies alongside academic labs at institutions such as Yale and Stanford. The remainder goes to supporting external startups in oncology. Jobs highlighted the firm's commitment to developing new therapies by creating entirely new medicine categories, such as epigenetic gene editing and targeted gene editing delivery methods. Despite the biotech sector’s previous post-pandemic slump and investors’ conservative tendencies, the environment has improved with pharma companies becoming acquisitive again, motivated by a historic wave of blockbuster drug patent expirations and abundant cash reserves.

AI's role in healthcare is expanding beyond drug discovery into clinical trial efficiencies and hospital operations, according to Jobs. For example, AI-driven synthetic control arms can reduce clinical trial sizes and duration significantly, a change the FDA supports. Innovations like targeting previously “undruggable” genes such as KRAS and p53 are now within reach, largely due to AI’s ability to tackle complex protein interactions that were once inaccessible to traditional drug design. Yosemite’s portfolio reflects this progress, with multiple companies pursuing these challenging targets to achieve breakthroughs in cancer treatment.

While optimistic about biotech's rapid advancements, Jobs remains cautious about the longevity industry, emphasizing the complexity of aging and the absence of a unified theory. He also addresses challenges such as federal funding uncertainties for NIH and advises startup founders to carefully navigate partnerships with big pharma, which can offer funding but may limit strategic options due to shifting priorities. Fundamentally, Jobs’ vision for Yosemite is about taking an active role in creating cures, leveraging AI, philanthropy, and bold science to transform oncology treatment at an unprecedented pace.